These FTSE shares don’t have the highest yields. But Edward Sheldon believes they could deliver attractive returns in the ...

GSK settles 93% of Zantac lawsuits with a $2.2 billion payout, easing investor concerns. However, doubts over its future ...

We recently published an article titled Jim Cramer on Super Micro Computer and Other Stocks. In this article, we are going to ...

The UK based drug firm GSK has agreed to pay up to $2.2bn (£1.7bn; €2bn) to settle claims that the heartburn drug ranitidine (previously marketed in the US as Zantac) caused cancer. The deal, ...

Victoria’s Secret and the Unraveling of an American icon, authors Lauren Sherman and Chantal Fernandez weave together the ...

Zantac was pulled from shelves in 2019 amid panic that a key ingredient - ranitidine - could cause cancer, plunging GSK and ...

GSK to resolve 93% of US state court Zantac product liability cases for up to $2.2 billion: London, UK Friday, October 11, 2024, 14:00 Hrs [IST] GSK plc announced that it has reac ...

GSK shares jumped on Thursday after the UK drugmaker reached a settlement of up to $2.2bn to resolve the vast majority of cases linked to its heartburn medicine Zantac.

London’s FTSE 100 was down 6.01 points, or 0.07%, to close at 8,237.73, with housebuilders among the stocks dragging on the ...

Lawyers representing 10 groups of plaintiffs, or 80,000 liability cases across the US, have backed the payout. There remain another few thousand cases not covered by the payout. GSK will also pay a ...

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of ...

GSK's share price rose 6% after settling 93% of Zantac cases, impacting Q3 earnings; forward non-GAAP P/E remains reasonable ...